Hennion & Walsh Asset Management Inc. Buys 316,209 Shares of Altimmune, Inc. $ALT

Hennion & Walsh Asset Management Inc. increased its stake in Altimmune, Inc. (NASDAQ:ALT) by 156.5% in the 2nd quarter, Holdings Channel reports. The firm owned 518,198 shares of the company’s stock after purchasing an additional 316,209 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Altimmune were worth $1,575,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. PVG Asset Management Corp acquired a new position in Altimmune during the first quarter valued at approximately $204,000. Bank of America Corp DE boosted its holdings in shares of Altimmune by 48.6% during the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after buying an additional 186,420 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Altimmune by 101.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 35,650 shares of the company’s stock worth $110,000 after buying an additional 17,967 shares during the period. The Manufacturers Life Insurance Company grew its stake in Altimmune by 26.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company’s stock valued at $107,000 after buying an additional 7,167 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new position in Altimmune in the 1st quarter valued at $33,000. Institutional investors own 78.05% of the company’s stock.

Analyst Ratings Changes

ALT has been the topic of several recent analyst reports. Leerink Partners initiated coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Citizens Jmp cut their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Altimmune Stock Down 2.3%

ALT opened at $2.93 on Thursday. The firm has a market cap of $569.80 million, a price-to-earnings ratio of -3.15 and a beta of 0.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56. The firm’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $3.42. Altimmune, Inc. has a twelve month low of $2.56 and a twelve month high of $6.44.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Equities research analysts anticipate that Altimmune, Inc. will post -0.64 EPS for the current fiscal year.

Altimmune Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.